Trial Profile
Nivolumab maintenance as monotherapy after carboplatine plus nab-paclitaxel for first-line treatment of advanced Non-small-cell lung cancer: Feasibility study
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 04 Aug 2017
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 01 Aug 2017 Status changed from not yet recruiting to recruiting.
- 01 Aug 2017 New trial record